Intramuscular vs. Subcutaneous: Rethinking Influenza Vaccination Strategy in Japan
- PMID: 38314405
- PMCID: PMC10834209
- DOI: 10.31662/jmaj.2023-0122
Intramuscular vs. Subcutaneous: Rethinking Influenza Vaccination Strategy in Japan
Abstract
In Japan, inactivated vaccines, including the influenza vaccine, are administered subcutaneously, which is contrary to global recommendations for intramuscular injections. This practice is attributed to historical medical incidents and unchallenged conventions. However, this outdated method, which differs from that of international standards and is linked with less immunogenicity and more adverse reactions, may contribute to vaccination hesitancy. Therefore, with the adoption of intramuscular vaccination administration, which was widely adopted in the coronavirus disease 2019 vaccination, a shift in the Japanese health policy to conform to international standards potentially improves vaccine acceptance and effectiveness.
Keywords: COVID-19; Influenza; International Standards; Japan; Subcutaneous Vaccination.
Copyright © Japan Medical Association.
Conflict of interest statement
Dr. Ozaki reported personal fees from Medical Network Systems Inc. and Kyowa Kirin Co. Ltd. outside the submitted work. Dr. Tanimoto reported personal fees from Medical Network Systems Inc. and Bionics Co. Ltd. outside the submitted work.
Similar articles
-
Immunogenicity and safety of high-dose quadrivalent influenza vaccine in Japanese adults ≥65 years of age: a randomized controlled clinical trial.Hum Vaccin Immunother. 2020 Apr 2;16(4):858-866. doi: 10.1080/21645515.2019.1677437. Epub 2019 Nov 19. Hum Vaccin Immunother. 2020. PMID: 31634025 Free PMC article. Clinical Trial.
-
The safety, immunogenicity, and acceptability of inactivated influenza vaccine delivered by microneedle patch (TIV-MNP 2015): a randomised, partly blinded, placebo-controlled, phase 1 trial.Lancet. 2017 Aug 12;390(10095):649-658. doi: 10.1016/S0140-6736(17)30575-5. Epub 2017 Jun 27. Lancet. 2017. PMID: 28666680 Free PMC article. Clinical Trial.
-
Reactogenicity and immunogenicity of an inactivated influenza vaccine administered by intramuscular or subcutaneous injection in elderly adults.Vaccine. 2006 Mar 20;24(13):2395-402. doi: 10.1016/j.vaccine.2005.11.057. Epub 2005 Dec 13. Vaccine. 2006. PMID: 16406171 Clinical Trial.
-
Enhancing Immunogenicity of Influenza Vaccine in the Elderly through Intradermal Vaccination: A Literature Analysis.Viruses. 2022 Nov 3;14(11):2438. doi: 10.3390/v14112438. Viruses. 2022. PMID: 36366536 Free PMC article. Review.
-
Allergic reactions to Japanese encephalitis vaccine.Immunol Allergy Clin North Am. 2003 Nov;23(4):665-97. doi: 10.1016/s0889-8561(03)00102-4. Immunol Allergy Clin North Am. 2003. PMID: 14753386 Review.
References
-
- Okubo Y, Uda K, Miyairi I. Trends in influenza and related health resource use during 2005-2021 among children in Japan. Pediatr Infect Dis J. 2023;42(8):648-53. - PubMed
-
- Centers for Disease Control and Prevention. Vaccine effectiveness: how well do flu vaccines work? [Internet]. [cited 2023 Oct 17]. Available from: https://www.cdc.gov/flu/vaccines-work/vaccineeffect.htm.
LinkOut - more resources
Full Text Sources